With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape

 
• By Alaric DeArment

The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.

Moderna announced its Q4 and full-year 2022 earnings on 23 February • Source: Shutterstock

More from Earnings

More from Business